Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Mereo BioPharma Group stock

Own Mereo BioPharma Group stock in just a few minutes.

Fact checked

Mereo BioPharma Group plc is a biotechnology business based in the US. Mereo BioPharma Group shares (MREO) are listed on the NASDAQ and all prices are listed in US Dollars. Mereo BioPharma Group employs 50 staff and has a market cap (total outstanding shares value) of USD$416.4 million.

How to buy shares in Mereo BioPharma Group

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Mereo BioPharma Group. Find the stock by name or ticker symbol: MREO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Mereo BioPharma Group reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Mereo BioPharma Group, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Mereo BioPharma Group. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Mereo BioPharma Group share price

Use our graph to track the performance of MREO stocks over time.

Mereo BioPharma Group shares at a glance

Information last updated 2021-02-24.
52-week rangeUSD$0.69 - USD$4.711
50-day moving average USD$3.2509
200-day moving average USD$2.7968
Wall St. target priceUSD$8
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.4313

Buy Mereo BioPharma Group shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Mereo BioPharma Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Mereo BioPharma Group financials

Gross profit TTM USD$0
Return on assets TTM -20.81%
Return on equity TTM -344.02%
Profit margin 0%
Book value N/A
Market capitalisation USD$416.4 million

TTM: trailing 12 months

Shorting Mereo BioPharma Group shares

There are currently 7.1 million Mereo BioPharma Group shares held short by investors – that's known as Mereo BioPharma Group's "short interest". This figure is 7.5% up from 6.6 million last month.

There are a few different ways that this level of interest in shorting Mereo BioPharma Group shares can be evaluated.

Mereo BioPharma Group's "short interest ratio" (SIR)

Mereo BioPharma Group's "short interest ratio" (SIR) is the quantity of Mereo BioPharma Group shares currently shorted divided by the average quantity of Mereo BioPharma Group shares traded daily (recently around 716252.83975659). Mereo BioPharma Group's SIR currently stands at 9.86. In other words for every 100,000 Mereo BioPharma Group shares traded daily on the market, roughly 9860 shares are currently held short.

However Mereo BioPharma Group's short interest can also be evaluated against the total number of Mereo BioPharma Group shares, or, against the total number of tradable Mereo BioPharma Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Mereo BioPharma Group's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Mereo BioPharma Group shares in existence, roughly 100 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Mereo BioPharma Group shares, roughly 0 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Mereo BioPharma Group.

Find out more about how you can short Mereo BioPharma Group stock.

Mereo BioPharma Group share dividends

We're not expecting Mereo BioPharma Group to pay a dividend over the next 12 months.

Mereo BioPharma Group share price volatility

Over the last 12 months, Mereo BioPharma Group's shares have ranged in value from as little as $0.69 up to $4.711. A popular way to gauge a stock's volatility is its "beta".

MREO.US volatility(beta: 0.75)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mereo BioPharma Group's is 0.7463. This would suggest that Mereo BioPharma Group's shares are less volatile than average (for this exchange).

Mereo BioPharma Group overview

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site